News & Topics
News&Topics

2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2022.05.18
Chimerix announces sale of brincidofovir to Emergent BioSolutions
2022.05.16
Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
2022.05.11
Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
2022.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
2022.04.01
Joint research agreement with the National Cancer Center on rare cancers
2022.03.31
Notice of Renewal of Syndicated Loan Agreement
2022.03.30
Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
2022.03.29
Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
2022.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2022.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2022.03.25
Analyst Report[Full report] (Shared Research)
2022.03.09
Information on Shareholders' Meeting: Updated the Page
2022.03.08
SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
2022.03.07
SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
2022.02.28
SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
2022.02.25
Response to marketing approvals of generic products
2022.02.24
Notification of Amendments to the Articles of Incorporation
2022.02.24
Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
2022.02.24
SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
2022.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
2022.02.10
Notice concerning non-operating expenses
2022.02.10
Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
2022.01.31
Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
2022.01.18
SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
2022.01.06
Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo